OBJECTIVE: To report long-term, health-related quality-of-life (HRQOL) outcomes in patients treated with transoral robotic surgery (TORS). STUDY DESIGN: Prospective, longitudinal, clinical study on functional and HRQOL outcomes in TORS. SETTING: University tertiary care facility. SUBJECTS AND METHODS: Patients who underwent TORS were asked to complete a Head and Neck Cancer Inventory before treatment and at 3 weeks and 3, 6, and 12 months postoperatively. Demographic, clinicopathological, and follow-up data were collected. RESULTS: Sixty-four patients who underwent TORS were enrolled. A total of 113 TORS procedures were performed. The mean follow-up time was 16.3 ± 7.49 months. The HRQOL was assessed at 3 weeks and at 3, 6, and 12 months, with a response rate of 78%, 44%, 41%, and 28%, respectively. TORS was performed most frequently for squamous cell carcinoma (88%). There was a decrease from baseline in the speech, eating, aesthetic, social, and overall QOL domains immediately after treatment. At the 1-year follow-up, the HRQOL scores in the aesthetic, social, and overall QOL domains were in the high domain. Patients with malignant lesions had significantly lower postoperative HRQOL scores in the speech, eating, social, and overall QOL domains (P < .05). Patients who underwent adjuvant radiation therapy or chemotherapy and radiation therapy had lower postoperative scores in the eating, social, and overall QOL domains (P < .05). CONCLUSION: The preliminary data show that patients who undergo TORS for malignancies and receive adjuvant therapy tend to have lower HRQOL outcomes. TORS is a promising, minimally invasive, endoscopic alternative surgical treatment of laryngopharyngeal tumors.
OBJECTIVE: To report long-term, health-related quality-of-life (HRQOL) outcomes in patients treated with transoral robotic surgery (TORS). STUDY DESIGN: Prospective, longitudinal, clinical study on functional and HRQOL outcomes in TORS. SETTING: University tertiary care facility. SUBJECTS AND METHODS: Patients who underwent TORS were asked to complete a Head and Neck Cancer Inventory before treatment and at 3 weeks and 3, 6, and 12 months postoperatively. Demographic, clinicopathological, and follow-up data were collected. RESULTS: Sixty-four patients who underwent TORS were enrolled. A total of 113 TORS procedures were performed. The mean follow-up time was 16.3 ± 7.49 months. The HRQOL was assessed at 3 weeks and at 3, 6, and 12 months, with a response rate of 78%, 44%, 41%, and 28%, respectively. TORS was performed most frequently for squamous cell carcinoma (88%). There was a decrease from baseline in the speech, eating, aesthetic, social, and overall QOL domains immediately after treatment. At the 1-year follow-up, the HRQOL scores in the aesthetic, social, and overall QOL domains were in the high domain. Patients with malignant lesions had significantly lower postoperative HRQOL scores in the speech, eating, social, and overall QOL domains (P < .05). Patients who underwent adjuvant radiation therapy or chemotherapy and radiation therapy had lower postoperative scores in the eating, social, and overall QOL domains (P < .05). CONCLUSION: The preliminary data show that patients who undergo TORS for malignancies and receive adjuvant therapy tend to have lower HRQOL outcomes. TORS is a promising, minimally invasive, endoscopic alternative surgical treatment of laryngopharyngeal tumors.
Authors: K Bjordal; M Ahlner-Elmqvist; E Hammerlid; M Boysen; J F Evensen; A Biörklund; M Jannert; T Westin; S Kaasa Journal: Laryngoscope Date: 2001-08 Impact factor: 3.325
Authors: Pepijn A Borggreven; Neil K Aaronson; Irma M Verdonck-de Leeuw; Martin J Muller; Milou L C H Heiligers; Remco de Bree; Johannes A Langendijk; C René Leemans Journal: Oral Oncol Date: 2007-02-16 Impact factor: 5.337
Authors: Marc P van der Schroeff; Wynia Derks; Gerrit Jan Hordijk; Rob J de Leeuw Journal: Eur Arch Otorhinolaryngol Date: 2006-11-11 Impact factor: 2.503
Authors: Michael J Persky; William G Albergotti; Tanya J Rath; Mark W Kubik; Shira Abberbock; Mathew Geltzeiler; Seungwon Kim; Umamaheswar Duvvuri; Robert L Ferris Journal: Otolaryngol Head Neck Surg Date: 2017-11-28 Impact factor: 3.497
Authors: Arun Sharma; Sapna Patel; Fred M Baik; Grant Mathison; Brendan H G Pierce; Samir S Khariwala; Bevan Yueh; Stephen M Schwartz; Eduardo Méndez Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-07-01 Impact factor: 6.223
Authors: S N Rogers; R S Pinto; J Lancaster; F Bekiroglu; D Lowe; S Tandon; T M Jones Journal: Eur Arch Otorhinolaryngol Date: 2016-04-18 Impact factor: 2.503